Jalal Alghabra, PA

Jalal Alghabra practices at Dermatology and Plastic Surgery Associates, S.C. in Bourbonnais, Illinois.

Jalal Alghabra's NPI, 1023497880, was assigned on May 27, 2015. Jalal Alghabra holds Virginia license 0110005989.

Jalal Alghabra's primary practice is Dermatology and Plastic Surgery Associates, S.C., at 595 William Latham Dr, Bourbonnais, IL 60914 in Kankakee County. The practice phone is (815) 744-8554.

Jalal Alghabra's primary practice is Dermatology and Plastic Surgery Associates, S.C. in Bourbonnais, Illinois. Jalal Alghabra is also affiliated with Mary Washington Hospital. The medical group on file is Pinnacle Dermatology. Dmand AI also links Jalal Alghabra to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Jalal Alghabra practices, 2 sites in all. Vendor and product names are available with a free account.

Physician assistant is Jalal Alghabra's primary specialty in the NPI Registry, under taxonomy code 363A00000X. Jalal Alghabra is board certified in certified physician assistant by the National Commission on Certification of Physician Assistants (NCCPA). Dmand AI has Jalal Alghabra's licenses on file in 3 states: Virginia, Michigan and North Carolina.

Dmand AI lists acne, acute skin infection, ankle or foot injury, benign or precancerous skin growths, bursitis, chest wall injury, cold sores or genital herpes and contact dermatitis among the conditions Jalal Alghabra treats.

CMS data shows 10,433 Medicare services from Jalal Alghabra across 29 procedure codes in 2024, for 2,112 Medicare patients. Medicare paid $325,844 for them. Every service was in an office.

CMS counts 2,112 Medicare patients who saw Jalal Alghabra in 2024. The largest group is 65 to 74, with 970 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 2% are also on Medicaid. Their average risk score is 0.95, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Jalal Alghabra's median patient age at 70, with 50% women.

In 2024, Jalal Alghabra wrote 2,232 Medicare Part D claims for 737 patients. 88% of them were for generic drugs. CMS names the drug for 2,033 of them, across 33 drugs with 11 or more claims each, at $1,385,723 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Jalal Alghabra for performance year 2024, reported as part of a group. Jalal Alghabra accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 221 general payments to Jalal Alghabra from 22 drug and device companies in 2025. Speaker and faculty fees make up the largest share, 64% of the total. Janssen Pharmaceuticals, Inc paid the most, $13,033.